Development of Vitiligo in Patients Treated with BRAF/MEK Inhibitors: A Systematic Review

BRAF and MEK inhibitors have emerged as key therapies in the treatment of metastatic melanoma through selective inhibition of the mitogen activated protein kinase (MAPK) pathway. A rare side effect of BRAF and MEK inhibitors is the development of vitiligo. This systematic review aims to summarize the existing literature on new-onset or exacerbations of vitiligo following BRAF, MEK, or BRAF/MEK combination inhibitor therapy.